{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:05:46Z","timestamp":1789967146931,"version":"4.0.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between receiving a resilience-focused program in addition to standard care and depressive symptoms and medication adherence among patients with CHB receiving antiviral therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort study, 200 patients diagnosed with CHB and treated at our hospital's hepatology clinic between July 2022 and June 2025 were included. Based on historical records, 100 patients who voluntarily completed a structured 12-week resilience promotion program in addition to standard care formed the observation group, and 100 patients who received standard care only formed the control group. Primary outcomes at the 6-month follow-up were depressive symptom severity measured by the Patient Health Questionnaire-9 (PHQ-9) and medication adherence measured by the Medication Possession Ratio (MPR). Secondary outcomes included resilience (Connor-Davidson Resilience Scale-10, CD-RISC-10), virological response, alanine aminotransferase (ALT) normalization, quality of life (SF-36), adverse events, and healthcare utilization. To account for potential confounding by indication and baseline imbalances, multivariable linear, logistic, and Poisson regression models were used, with adjusted effect estimates and 95% confidence intervals reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At the 6-month follow-up, the observation group had lower depression scores (6.78\u2009\u00b1\u20093.45 vs. 10.23\u2009\u00b1\u20094.12), higher MPR (0.92\u2009\u00b1\u20090.08 vs. 0.78\u2009\u00b1\u20090.15), and higher resilience scores (32.45\u2009\u00b1\u20095.67 vs. 26.78\u2009\u00b1\u20096.34). Virological response (85.0% vs. 70.0%; adjusted OR 2.46, 95% CI 1.35 to 4.48) and ALT normalization (80.0% vs. 65.0%; adjusted OR 2.01, 95% CI 1.10 to 3.67) were more frequent in the observation group. SF-36 physical and mental component scores were also higher in the observation group. Adverse event incidence was similar between groups. The observation group had fewer unplanned outpatient visits (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.045), and Poisson regression confirmed fewer outpatient visits in the observation group (adjusted rate ratio 0.72, 95% CI 0.56 to 0.93). However, because allocation was non-randomized, these associations may be affected by self-selection and residual confounding.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this retrospective cohort study, receiving a resilience-focused program in addition to standard care was associated with lower depressive symptoms, better medication adherence, and more favorable virological and biochemical outcomes in patients with CHB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1832041","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:28:43Z","timestamp":1789964923000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Depression and medication adherence among chronic hepatitis B patients receiving resilience-based care versus standard care during antiviral therapy: a retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiao","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Hefei Third People\u2019s Hospital, Third Clinical Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhao","sequence":"additional","affiliation":[{"name":"Nursing Department of Hefei Third People\u2019s Hospital, Third Clinical Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hefei Third People\u2019s Hospital, Third Clinical Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hefei Third People\u2019s Hospital, Third Clinical Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e70545","DOI":"10.1111\/liv.16255","article-title":"Indeterminate phase\/grey zone of chronic hepatitis B","volume":"46","author":"Franz\u00e8","year":"2026","journal-title":"Liver Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3760\/cma.j.cn501113-20240521-00258","article-title":"Research progress on new drugs for the treatment of chronic hepatitis B virus infection","volume":"33","author":"Yu","year":"2025","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e70360","DOI":"10.1002\/jmv.70360","article-title":"Single-Cell atlas of the peripheral immune response in patients with chronic hepatitis B","volume":"97","author":"Huang","year":"2025","journal-title":"J Med Virol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1111\/apt.70613","article-title":"Increased risk for liver disease in patients with chronic hepatitis B virus infection and low-level viraemia","volume":"63","author":"Kwo","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1806527","DOI":"10.3389\/fimmu.2026.1806527","article-title":"Emerging antiviral drugs and immunotherapy for chronic hepatitis B and associated liver disease","volume":"17","author":"Zhu","year":"2026","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1097\/MJT.0000000000001721","article-title":"Advances in the pharmacological management of chronic hepatitis B","volume":"31","author":"Evans","year":"2024","journal-title":"Am J Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"106441","DOI":"10.1016\/j.antiviral.2026.106441","article-title":"Therapeutic vaccination for chronic hepatitis B: why most vaccines failed and what may work","volume":"252","author":"Bertoletti","year":"2026","journal-title":"Antiviral Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e70184","DOI":"10.1111\/jvh.70184","article-title":"Hepatitis B surface antigen loss and improved clinical outcomes in US individuals with chronic hepatitis B virus infection","volume":"33","author":"Drysdale","year":"2026","journal-title":"J Viral Hepat"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2515131","article-title":"Phase 3 results of bepirovirsen treatment for chronic hepatitis B virus infection","volume":"394","author":"Hou","year":"2026","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/jvh.13952","article-title":"Modelling the potential impact of global hepatitis B vaccination on the burden of chronic hepatitis B in the United States","volume":"31","author":"Downs","year":"2024","journal-title":"J Viral Hepat"},{"key":"B11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13293-026-00826-8","article-title":"Sex differences in the clinical outcomes of chronic hepatitis B infection among paediatric patients","volume":"17","author":"Ouyang","year":"2026","journal-title":"Biol Sex Differ"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1546545","DOI":"10.3389\/fpsyt.2025.1546545","article-title":"Burden of psychological symptoms and disorders among individuals with hepatitis B: a systematic review, meta-analysis and meta-regression","volume":"16","author":"Low","year":"2025","journal-title":"Front Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.14744\/hf.2025.74529","article-title":"Hepatic steatosis is associated with HBsAg seroclearance in patients with chronic hepatitis B virus infection but it is also associated with disease progression","volume":"7","author":"Bodakci","year":"2026","journal-title":"Hepatol Forum"},{"key":"B14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12985-026-03190-6","article-title":"Predictive value of serum S100A8\/A9 for liver dysfunction in pregnant women with chronic hepatitis B","volume":"23","author":"Geng","year":"2026","journal-title":"Virol J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0303124","DOI":"10.1371\/journal.pone.0303124","article-title":"Hepatitis B infection: evaluation of demographics and treatment of chronic hepatitis B infection in northern-western Tanzania","volume":"19","author":"Mlewa","year":"2024","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"199103","DOI":"10.1016\/j.virusres.2023.199103","article-title":"Association of HLADQ-B1 polymorphisms in three generations of chronic hepatitis B patients","volume":"329","author":"Zhao","year":"2023","journal-title":"Virus Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3390\/biom13081217","article-title":"Chronic hepatitis B infection: new approaches towards cure","volume":"13","author":"Albano","year":"2023","journal-title":"Biomolecules"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2023.0431","article-title":"Comprehensive approach to controlling chronic hepatitis B in China","volume":"30","author":"Shan","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3390\/v15051168","article-title":"Hepatitis B core antibody level: a surrogate marker for host antiviral immunity in chronic hepatitis B virus infections","volume":"15","author":"Ayusso","year":"2023","journal-title":"Viruses"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2174\/1568026623666230413081527","article-title":"Chronic hepatitis B infection: current and emerging therapeutic strategies","volume":"23","author":"Singh","year":"2023","journal-title":"Curr Top Med Chem"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1156923","DOI":"10.3389\/fmicb.2023.1156923","article-title":"Plasma virome dynamics in chronic hepatitis B virus infected patients","volume":"14","author":"Thijssen","year":"2023","journal-title":"Front Microbiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1345672","DOI":"10.3389\/fimmu.2024.1345672","article-title":"The novel mechanism facilitating chronic hepatitis B infection: immunometabolism and epigenetic modification reprogramming","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/jvh.13852","article-title":"Incidence and factors influencing sleep disorders in patients with chronic hepatitis B infection: a case-control study","volume":"30","author":"Wu","year":"2023","journal-title":"J Viral Hepat"},{"key":"B24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cgh.2024.05.012","article-title":"Predictors of functional cure of chronic hepatitis B virus infection: a long-term follow-up study","volume":"23","author":"Pizzo","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1204567","DOI":"10.3389\/fphys.2023.1204567","article-title":"Ageing and non-liver comorbidities in population with chronic hepatitis B infection in the western Pacific region from 1990 to 2019","volume":"14","author":"Xie","year":"2023","journal-title":"Front Physiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"20220578","DOI":"10.1515\/biol-2022-0578","article-title":"Exosomal HBV-DNA for diagnosis and treatment monitoring of chronic hepatitis B","volume":"18","author":"Feng","year":"2023","journal-title":"Open Life Sci"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1832041\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:28:46Z","timestamp":1789964926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1832041\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":26,"alternative-id":["10.3389\/fmed.2026.1832041"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1832041","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1832041"}}